ArticleJournal of cancer survivorship : research and practice2026
Symptom burden among long-term survivors of young adult cancer: a report from the Project Milestones cohort.
Article in Journal of cancer survivorship : research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeAlthough late effects and their symptomatology are well described for childhood cancer survivors, less is known about survivors of young adult (YA) cancer. Our aim was to characterize symptom burden among long-term survivors of YA cancer.
methodsProject Milestones is a cross-sectional cohort survey study assessing benchmarks of emerging adulthood among 3-10-year cancer survivors diagnosed 21-39 years old. We analyzed responses from the first half of cohort participants to 22 questions that screened for current, clinically significant symptoms. Statistical analyses included Chi-square, Fisher exact, and negative binomial regression tests.
resultsThere were 1,025 evaluable participants (68.9% female; 34.2% Hispanic; median age at diagnosis and survey 31 and 39 years, respectively; and 73% ≥ 5 years post-treatment). Cancer types were reproductive (male/female, 30.4%), leukemia/lymphoma (28.2%), thyroid (13.5%), breast (10.3%), melanoma (8.9%), and colorectal (8.8%). The most-endorsed symptoms were fatigue (39.4%), altered appearance (35.8%), cognitive problems (31.7%), general pain (28.0%), sensory neuropathy (24%), and urinary incontinence (20%). Over 70% reported at least 1 symptom; one-third reported ≥ 4. In adjusted analysis, cumulative symptom count was significantly higher among participants who were female (vs. male), Hispanic (vs. non-Hispanic White), had public insurance (vs. employer-sponsored), and received chemotherapy/radiation (vs. surgery) by 44%, 21%, 49%, and 71%, respectively.
conclusionsLong-term survivors of YA cancer report a substantial burden of persistent, clinically significant symptoms. IMPLICATIONS FOR CANCER SURVIVORS: Clinicians should emphasize the importance of sustained survivorship care and monitor for symptoms suggesting late effects. Further research is needed to understand their contributing factors and functional impact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.